Altimmune, Inc.

NasdaqGM:ALT Stock Report

Market Cap: US$545.5m

Altimmune Management

Management criteria checks 2/4

Altimmune's CEO is Vipin Garg, appointed in Nov 2018, has a tenure of 6.08 years. total yearly compensation is $5.48M, comprised of 11.3% salary and 88.7% bonuses, including company stock and options. directly owns 0.41% of the company’s shares, worth $2.24M. The average tenure of the management team and the board of directors is 4.1 years and 5.3 years respectively.

Key information

Vipin Garg

Chief executive officer

US$5.5m

Total compensation

CEO salary percentage11.3%
CEO tenure6.1yrs
CEO ownership0.4%
Management average tenure4.1yrs
Board average tenure5.3yrs

Recent management updates

Recent updates

Altimmune 2025: Redefining Obesity And MASH Treatment

Dec 16

Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health

Nov 13

Regulatory And Clinical Catalysts Ahead For Altimmune

Oct 28

Consider Buying Potential Takeover Target Altimmune

Oct 02

Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects

Sep 21

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Sep 12
We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Altimmune: Emerging Position In Competitive Space, But Risks Remain

Aug 27

Altimmune: Lean Muscle Fat Data Sends Stock Soaring - Competitors Will Take Note

Jun 24

Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive Returns

May 27

Buy Altimmune's Potential Market Disruption With Pemvidutide

Apr 12

Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place

Mar 27

Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally

Feb 27

Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment

Feb 12

Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

Feb 10
Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

Thoroughly Derisked, Altimmune Is Now A Great Buy

Jan 10

Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?

Oct 11
Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Jun 27
We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth

Feb 12
Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth

We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth

Oct 27
We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth

Altimmune: Overreaction On NASH Data Creates Buying Opportunity

Sep 15

Reassessing Altimmune

Sep 07

Altimmune sets new 52-week high on rising volume

Aug 31

Altimmune Q2 2022 Earnings Preview

Aug 10

Altimmune: Several Catalysts In 2 Large Market Indications This Year

Jun 29

Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation

Jun 27
Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation

Altimmune's New Avatar As A Liver Disease Player

Apr 07

Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation

Feb 01
Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation

Altimmune: Changing Focus To Pemvidutide In 2022

Jan 03

Altimmune: Changing The Thesis

Oct 16

CEO Compensation Analysis

How has Vipin Garg's remuneration changed compared to Altimmune's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$104m

Jun 30 2024n/an/a

-US$101m

Mar 31 2024n/an/a

-US$93m

Dec 31 2023US$5mUS$620k

-US$88m

Sep 30 2023n/an/a

-US$78m

Jun 30 2023n/an/a

-US$81m

Mar 31 2023n/an/a

-US$85m

Dec 31 2022US$3mUS$580k

-US$85m

Sep 30 2022n/an/a

-US$87m

Jun 30 2022n/an/a

-US$97m

Mar 31 2022n/an/a

-US$102m

Dec 31 2021US$3mUS$566k

-US$97m

Sep 30 2021n/an/a

-US$84m

Jun 30 2021n/an/a

-US$68m

Mar 31 2021n/an/a

-US$60m

Dec 31 2020US$1mUS$514k

-US$49m

Sep 30 2020n/an/a

-US$43m

Jun 30 2020n/an/a

-US$36m

Mar 31 2020n/an/a

-US$22m

Dec 31 2019US$815kUS$500k

-US$21m

Sep 30 2019n/an/a

-US$42m

Jun 30 2019n/an/a

-US$34m

Mar 31 2019n/an/a

-US$40m

Dec 31 2018US$2mUS$44k

-US$42m

Compensation vs Market: Vipin's total compensation ($USD5.48M) is above average for companies of similar size in the US market ($USD2.13M).

Compensation vs Earnings: Vipin's compensation has increased whilst the company is unprofitable.

CEO

Vipin Garg (66 yo)

6.1yrs

Tenure

US$5,482,089

Compensation

Dr. Vipin K. Garg, Ph D., has been the President, Chief Executive Officer and Director of Altimmune, Inc. since November 30, 2018. Dr. Garg joined Altimmune in November 2018 with over three decades of expe...

Leadership Team

NamePositionTenureCompensationOwnership
Vipin Garg
President6.1yrsUS$5.48m0.41%
$ 2.2m
Matthew Harris
Chief Medical Officer5.4yrsUS$2.24m0.077%
$ 422.8k
Raymond Jordt
Chief Business Officer1.9yrsUS$2.94m0.021%
$ 112.4k
Gregory Weaver
Chief Financial Officerless than a yearno datano data
Andrew Shutterly
Principal Financial & Accounting Officer and Corporate Controller1.8yrsno data0.016%
$ 87.2k
Bertrand Georges
Chief Technology Officer7.6yrsno datano data
M. Roberts
Chief Scientific Officer12yrsUS$1.41m0.061%
$ 332.3k
Tony Blandin
Vice President of Quality & Compliance Management2.8yrsno datano data

4.1yrs

Average Tenure

65.5yo

Average Age

Experienced Management: ALT's management team is considered experienced (4.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Vipin Garg
President6.1yrsUS$5.48m0.41%
$ 2.2m
Mitchel Sayare
Independent Chairman14.7yrsUS$119.68k0.037%
$ 202.2k
John Gill
Independent Director20.3yrsUS$103.68k0.0039%
$ 21.3k
Philip Hodges
Independent Director7.6yrsUS$115.68k0.012%
$ 67.0k
Klaus Schafer
Independent Director7.6yrsUS$104.68k0.013%
$ 70.4k
Catherine Sohn
Independent Director1.8yrsUS$273.47k0%
$ 0
Wayne Pisano
Independent Director6.3yrsUS$108.68k0.012%
$ 65.2k
Caroline Apovian
Member of Obesity Scientific Advisory Board2.4yrsno datano data
Diane Jorkasky
Independent Director4.6yrsUS$95.68k0%
$ 0
Rohit Loomba
Member of Mash Scientific Advisory Board2.4yrsno datano data
Mazen Noureddin
Member of Mash Scientific Advisory Board2.4yrsno datano data
Naga Chalasani
Member of Mash Scientific Advisory Board2.4yrsno datano data

5.3yrs

Average Tenure

71.5yo

Average Age

Experienced Board: ALT's board of directors are considered experienced (5.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 17:13
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Altimmune, Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
Joshua SchimmerEvercore ISI
Liisa BaykoEvercore ISI